oa Medical Treatment of Benign Prostatic Hyperplasa Where do we stand in 2004?

References

1. Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockers: a reflection form MTOPS. Curr Opin Urol. 2004; 14::17–20.
   [Google Scholar]
2. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology. 2001; 58::508–516.
   [Google Scholar]
3. Akduman B, Crawford ED. Terazosin, doxazosin and prazosin: Current clinical experience. Urology. 2001; 58:Suppl 1:49–54.
   [Google Scholar]
4. American Urological Association. AUA guidelines on the management of benign prostatic hyperplasia 2003. Available from URL: http://www.auanet.org/timssnet/products/ guidelines/bph_management.cfm.
5. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1 -adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36::1–13.
   [Google Scholar]
6. Schulowan CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol. 1999; 36::609–620.
   [Google Scholar]
7. Span PN, Voller MC, Smals AG, Swap EG, Schalken JA, Feneley MR, et al., Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzynamatic activity in the human prostate. J Urol. 1999; 161::332–337.
   [Google Scholar]
8. Andriole G, Ray P, Humphrey P, Gleave M, Rittmaster R. The impact of dutasteride, a novel dual 5 a-reductase inhibitor on both serum and intraprostatic androgens. Eur Urol suppl. 2003; 2:1:85. (Abstract 332).
   [Google Scholar]
9. Meconnell JJ, Bruskewitz R, Walsh PC, Andriole G, Lieber MM, Holtgrew e HL, et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998; 338::557–563.
   [Google Scholar]
10. Thompson IM, Goodman PJ, Tangen CM, Lucia ML, Miller GJ, Ford LG, et al., The influence of finasteride in the develop-ment of prostate cancer. N Engl J Med. 2003; 349::211–220.
    [Google Scholar]
11. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Androile G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase Types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002; 60::434–441.
    [Google Scholar]
12. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol. 2002; 12::15–18.
    [Google Scholar]
13. Lowe FC, Fagelman E. Phytotheapy in the treatment of benign prostatic hyperplasia: an update. Urology. 1999; 53::671–678.
    [Google Scholar]
14. Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004; 14::13–16.
    [Google Scholar]
15. Abrams P, Kaplans S, Millard R. Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity. Eur Urol. 2002; 1:Suppl:132.
    [Google Scholar]
16. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003; 326::841–844.
    [Google Scholar]
17. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al., Combi-nation treatment with an alpha blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomize, controlled study. J Urol. 2002; 169::2253–2256.
    [Google Scholar]
18. Debryne FM, Jardin A, Colloi D, et al., Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol. 1998; 34::169–175.
    [Google Scholar]
19. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al., The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Study, Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;:335–539.
    [Google Scholar]
20. Kirby RS, Roehrborm CG, Boyle P, Bartsch G, Jardin A, Cary MM, et al., Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptoma-tic benign prostatic hyperplasia: The prospective European doxazosin and combination therapy (PREDICT) trial. Urology. 2003; 61::119–126.
    [Google Scholar]
21. Bautista OM, Kusek JW, Nyberg LM, et al., Study design of the Medical Therapy Of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2001; 24::224–243.
    [Google Scholar]
22. Mc Connell ID. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial [abstract]. J Urol. 2002; 167::1042.
    [Google Scholar]
23. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170::530–547.
    [Google Scholar]